Cellular immuno-oncology – overcoming manufacturing and development obstacles to commercial success

CELL AND GENE THERAPY INSIGHTS

June 2021

Cellular immuno-oncology – overcoming manufacturing and development obstacles to commercial success

Download PDF

Innovator Insight

Navigating regulations: novel cell therapy platforms and their path to clinical manufacturing

Navigating regulations: novel cell therapy platforms and their path to clinical manufacturing

N Bauer, N Calhoun, A Davies et al.

CMC obstacles in cell and gene therapy: four solutions to solve six challenges

CMC obstacles in cell and gene therapy: four solutions to solve six challenges

Subbu Viswanathan, Marc Puich

Commentary

Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy

Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy

Marcelo Bravo, Timothy J Davies, Paul J Fairchild

Interview

Pursuing a fully closed cellular immunotherapy manufacturing model

Pursuing a fully closed cellular immunotherapy manufacturing model

Optimizing manufacturing processes to develop novel cell and gene therapies

Optimizing manufacturing processes to develop novel cell and gene therapies

Reflecting upon the GSK–UCL collaboration on viral vector bioprocess economics for <em>ex vivo</em> gene therapy commercialization

Reflecting upon the GSK–UCL collaboration on viral vector bioprocess economics for ex vivo gene therapy commercialization

Suzanne S Farid

A bright commercial future for off-the-shelf NK cell therapy

A bright commercial future for off-the-shelf NK cell therapy

Jan Spanholtz, Troels Jordansen, Volker Huppert

Viewpoint

Allogeneic T-cell therapies: from R&D lab to production facility

Allogeneic T-cell therapies: from R&D lab to production facility

Jakob Dupont, M.D., Joe Newell

Webinars

Navigating regulations - novel cell therapy platforms and their path to clinical manufacturing

Navigating regulations - novel cell therapy platforms and their path to clinical manufacturing

N Bauer, N Calhoun, A Davies et al.

Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Y Ji PhD, S Ensari PhD, N Moore PhD

Accelerating CAR-T process development: The power of process insight

Accelerating CAR-T process development: The power of process insight

Julia Hupfeld PhD